PROTAC technology for prostate cancer treatment
Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men. PrCa is marked by uncontrolled cellular growth that leads to abnormal enlargement of the prostate gland. The metastatic spread of PrCa is the primary cause of mortality, causing cancer cell dissemination to distant sites,...
Saved in:
| Main Authors: | Zhen Wang, Dingpeng Zhang, Hiroyuki Inuzuka, Wenyi Wei |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Compuscript Ltd
2025-01-01
|
| Series: | Acta Materia Medica |
| Online Access: | https://www.scienceopen.com/hosted-document?doi=10.15212/AMM-2024-0075 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Corrigendum to: PROTAC technology for prostate cancer treatment
by: Zhen Wang, et al.
Published: (2025-07-01) -
PROTACs targeting epigenetic proteins
by: Chao Zhang, et al.
Published: (2023-11-01) -
Application of PROTACs in target identification and validation
by: Yang Liu, et al.
Published: (2024-02-01) -
Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer
by: Zhao K, et al.
Published: (2025-06-01) -
Advancing Design Strategy of PROTACs for Cancer Therapy
by: Hang Luo, et al.
Published: (2025-07-01)